연구용
제품 번호: S1692
| 관련 타겟 | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase |
|---|---|
| 기타 Alkylating Agent 억제제 | Berberine (Umbellatine) MNNG (1-Methyl-3-nitro-1-nitrosoguanidine) |
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| SK-N-SH cells | Proliferation assay | 10-100 μM | 72 h | Antiproliferative activity against human SK-N-SH cells at 10 to 100 uM after 72 hrs by MTT assay | 24814532 | |
| SiMa cells | Proliferation assay | 10-100 μM | 72 h | Antiproliferative activity against human SiMa cells at 10 to 100 uM after 72 hrs by MTT assay | 24814532 | |
| Kelly cells | Proliferation assay | 10-100 μM | 72 h | Antiproliferative activity against human Kelly cells at 10 to 100 uM after 72 hrs by MTT assay | 24814532 | |
| LS cells | Proliferation assay | 10-100 μM | 72 h | Antiproliferative activity against human LS cells at 10 to 100 uM after 72 hrs by MTT assay | 24814532 | |
| K562 | Apoptosis assay | 48 hrs | Induction of apoptosis in imatinib mesylate-resistant human K562 cells after 48 hrs | 18339455 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | |||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 246.3 | 화학식 | C6H14O6S2 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 55-98-1 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | NSC-750 | Smiles | CS(=O)(=O)OCCCCOS(=O)(=O)C | ||
|
In vitro |
DMSO
: 49 mg/mL
(198.94 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| 시험관 내(In vitro) |
Busulfan inhibits the cobblestone area-forming cell frequency but fails to cause a significant increase in apoptosis in hematopoietic stem cell alike cells and progenitors. This compound inhibits the hematopoietic function of HSC alike cells and progenitors via an apoptosis-independent mechanism. It induces bone marrow hematopoietic cell senescence associated with an increased expression of p16Ink4a and p19Arf in a time-dependent manner. This chemical, an alkylating agent that causes DNA damage by cross-linking DNAs and DNA and proteins, induces senescence in normal human diploid WI38 fibroblasts through the extracellular signal-regulated kinase (Erk) and p38 mitogen-activated protein kinase (p38 MAPK) cascade independent of the p53-DNA damage pathway. It induces a transient reduction in GSH but a continuous increase in ROS production. This compound-induced hypophosphorylation of Rb prevents apoptosis of spermatogonial stem cells by inhibiting PCNA expression in testicular cells. |
|---|---|
| 생체 내(In vivo) |
Busulfan-treated mice exhibit a marked increase in apoptosis and a decrease in testis weight. This compound is administered at the rate of 40 mg/kg body weight to induce a maximal number of apoptotic cells while minimizing the number of necrotic cells. Its conditioning and irradiation results in comparable sensitivity of HSC detection as evaluated by limiting dilution analysis in NOD/SCID mice. This chemical-transplanted mice has slow and incomplete lymphoid engraftment. It (20 mg/kg to 100 mg/kg) provides dose-dependent congenic lymphoid reconstitution in mice. |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | p-Y534 AR / AR Ack1 / Src |
|
27904688 |
| Growth inhibition assay | Cell viability |
|
24815002 |
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT04451200 | Not yet recruiting | Acute Leukemia|Mielodysplasic Syndrome|Myeloproliferative Neoplasm |
Institut Paoli-Calmettes |
November 2020 | Phase 2 |
| NCT03601286 | Recruiting | Severe Combined Immunodeficiency X-Linked |
Great Ormond Street Hospital for Children NHS Foundation Trust |
December 21 2018 | Phase 1 |
| NCT03235973 | Unknown status | Leukemia Myeloid Acute|Leukemia Lymphoblastic Acute |
Institut Paoli-Calmettes |
April 28 2018 | Phase 1 |
질문 1:
How can I reconstitute it for in vivo studies?
답변:
This compound also can be dissolved in 2% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5mg/ml as a clear solution. When preparing the solution, please dissolve it in DMSO clearly first. Then add PEG and Tween. After they mixed well, dilute with water. It in this formulation is not suitable for long-term storage. Please make the fresh solution each time before use.